| Study |
Time |
Treatment |
Outcome (scale) |
N of Pts |
Baseline Mean |
End of Study Mean |
Absolute Benefit |
Relative Difference |
| Carrabba 1995 |
1‐4 wk |
E: Hyalgan (5) |
Pain on movement (0‐100 mm VAS) |
20 |
63.3 |
41.8 |
‐13.5 (I) |
‐21% (I) |
| |
|
C: Saline |
|
20 |
64.4 |
56.4 |
|
|
| Carrabba 1995a |
1‐4 wk |
E: Hyalgan (3) |
Pain on movement (0‐100 mm VAS) |
20 |
64.2 |
46.0 |
‐10.2 (I) |
‐15.8% (I) |
| |
|
C: Saline |
|
20 |
64.4 |
56.4 |
|
|
| Carrabba 1995b |
1‐4 wk |
E: Hyalgan (5) |
Pain on movement (0‐100 mm VAS) |
20 |
63.3 |
41.8 |
‐16.7 (I) |
‐25.9% (I) |
| |
|
C: Arthrocentesis |
|
20 |
64.5 |
59.7 |
|
|
| Carrabba 1995c |
1‐4 wk |
E: Hyalgan (3) |
Pain on movement (0‐100 mm VAS) |
20 |
64.2 |
46.0 |
‐13.4 (I) |
‐20.8% (I) |
| |
|
C: Arthrocentesis |
|
20 |
64.5 |
59.7 |
|
|
| Corrado 1995 |
1‐4 wk |
E: Hyalgan |
Pain on movement (0‐100 mm VAS) |
19 |
71.2 |
35.4 |
‐18.5 (I) |
‐31.4% (I) |
| |
|
C: Saline |
|
16 |
58.9 |
41.6 |
|
|
| Creamer 1994 |
1‐4 wk |
E: Hyalgan |
Pain use related (0‐100 mm VAS) |
12 |
52.58 |
41.12 |
8.99 (W) |
16.5% (W) |
| |
|
C: Saline |
|
12 |
54.38 |
33.93 |
|
|
| Henderson 1994 |
1‐4 wk |
E: Hyalgan |
Pain active movement (0‐100 mm VAS) |
18 |
43.7 |
28.1 |
‐1.4 (I) |
‐2.3% (I) |
| |
|
C: Saline |
|
19 |
53.0 |
38.8 |
|
|
| Henderson 1994a |
1‐4 wk |
E: Hyalgan |
Pain active movement (0‐100 mm VAS) |
22 |
48.5 |
39.8 |
9.3 (W) |
18.9% (W) |
| |
|
C: Saline |
|
25 |
49.3 |
31.3 |
|
|
| Huskisson 1999 |
1‐4 wk |
E: Hyalgan |
Pain walking (0‐100 mm VAS) |
45 |
67.20 |
35.29 |
‐15.41 (I) |
‐23.88% (I) |
| |
|
C: Saline |
|
48 |
64.52 |
48.02 |
|
|
| Jubb 2003 |
1‐4 wk |
E: Hyalgan |
Pain on walking (0‐100 mm VAS) |
208 |
56.95 |
43.87 |
‐1.8 (I) |
‐3.3% (I) |
| |
|
C: Saline |
|
200 |
55.15 |
43.88 |
|
|
| Tsai 2003 |
1‐4 wk |
E: Hyalgan |
Pain on 50 foot walk (0‐100 mm VAS) |
100 |
47.85 |
22.60 |
‐4.0 (I) |
‐8.9% (I) |
| |
|
C: Saline |
|
98 |
45.15 |
23.92 |
|
|
| Carrabba 1995 |
5‐13 wk |
E: Hyalgan (5) |
Pain on movement (0‐100 mm VAS) |
20 |
63.3 |
42.10 |
‐16.6 (I) |
‐25.8% (I) |
| |
|
C: Saline |
|
20 |
64.4 |
59.80 |
|
|
| Carrabba 1995a |
5‐13 wk |
E: Hyalgan (3) |
Pain on movement (0‐100 mm VAS) |
20 |
64.2 |
47.80 |
‐11.8 (I) |
‐18.3% (I) |
| |
|
C: Saline |
|
20 |
64.4 |
59.80 |
|
|
| Carrabba 1995b |
5‐13 wk |
E: Hyalgan (5) |
Pain on movement (0‐100 mm VAS) |
20 |
63.3 |
42.10 |
‐19.9 (I) |
‐30.9% (I) |
| |
|
C: Arthrocentesis |
|
20 |
64.5 |
63.20 |
|
|
| Carrabba 1995c |
5‐13 wk |
E: Hyalgan (3) |
Pain on movement (0‐100 mm VAS) |
20 |
64.2 |
47.80 |
‐15.1 (I) |
‐23.4% (I) |
| |
|
C: Arthrocentesis |
|
20 |
64.5 |
63.20 |
|
|
| Corrado 1995 |
5‐13 wk |
E: Hyalgan |
Pain on movement (0‐100 mm VAS) |
19 |
71.2 |
29.70 |
‐25.8 (I) |
‐43.8% (I) |
| |
|
C: Saline |
|
16 |
58.9 |
43.20 |
|
|
| Creamer 1994 |
5‐13 wk |
E: Hyalgan |
Pain use related (0‐100 mm VAS) |
12 |
52.58 |
41.80 |
1.80 (W) |
3.3% (W) |
| |
|
C: Saline |
|
12 |
54.38 |
41.80 |
|
|
| Huskisson 1999 |
5‐13 wk |
E: Hyalgan |
Pain walking (0‐100 mm VAS) |
43 |
67.20 |
37.40 |
‐15.46 (I) |
‐23.96% (I) |
| |
|
C: Saline |
|
45 |
64.52 |
50.18 |
|
|
| Jubb 2003 |
5‐13 wk |
E: Hyalgan |
Pain on walking (0‐100 mm VAS) |
208 |
56.95 |
46.51 |
‐4.89 (I) |
‐8.9% (I) |
| |
|
C: Saline |
|
200 |
55.15 |
50.20 |
|
|
| Tsai 2003 |
5‐13 wk |
E: Hyalgan |
Pain on 50 foot walk (0‐100 mm VAS) |
100 |
47.85 |
19.32 |
‐3.16 (I) |
‐7.0% (I) |
| |
|
C: Saline |
|
98 |
45.15 |
19.78 |
|
|
| Huskisson 1999 |
14‐26 wk |
E: Hyalgan |
Pain walking (0‐100 mm VAS) |
39 |
67.20 |
39.44 |
‐16.92 (I) |
‐26.22% (I) |
| |
|
C: Saline |
|
40 |
64.52 |
53.68 |
|
|
| Jubb 2003 |
14‐26 wk |
E: Hyalgan |
Pain on walking (0‐100 mm VAS) |
208 |
56.95 |
50.06 |
‐1.88 (I) |
‐3.4% (I) |
| |
|
C: Saline |
|
200 |
55.15 |
50.14 |
|
|
| Tsai 2003 |
14‐26 wk |
E: Hyalgan |
Pain on 50 foot walk (0‐100 mm VAS) |
100 |
47.85 |
15.57 |
‐7.8 (I) |
‐17.3% (I) |
| |
|
C: Saline |
|
98 |
45.15 |
20.68 |
|
|
| Jubb 2003 |
45‐52 wk (RC) |
E: Hyalgan |
Pain on walking (0‐100 mm VAS) |
208 |
56.95 |
47.59 |
‐4.7 (I) |
‐8.4% (I) |
| |
|
C: Saline |
|
200 |
55.15 |
50.45 |
|
|
| Bragantini 1987 |
1‐4 wk |
E: Hyalgan |
Pain spontaneous (0‐100 mm VAS) |
19 |
47.74 |
17.12 |
‐29.5 (I) |
‐62.5% (I) |
| |
|
C: Saline |
|
18 |
47.29 |
46.21 |
|
|
| Grecomoro 1987 |
1‐4 wk |
E: Hyalgan |
Pain intensity (0‐100 mm VAS) |
20 |
50.71 |
14.55 |
‐22.9 (I) |
‐48.3% (I) |
| |
|
C: Phosphate buffer |
|
18 |
47.32 |
34.02 |
|
|
| Bragantini 1987 |
5‐13 wk |
E: Hyalgan |
Pain spontaneous (0‐100 mm VAS) |
19 |
47.74 |
15.59 |
‐31.8 (I) |
‐67.3% (I) |
| |
|
C: Saline |
|
18 |
47.29 |
46.95 |
|
|
| Grecomoro 1987 |
5‐13 wk |
E: Hyalgan |
Pain intensity (0‐100 mm VAS) |
20 |
50.71 |
20.80 |
‐17.8 (I) |
‐37.6% (I) |
| |
|
C: Phosphate buffer |
|
18 |
47.32 |
35.18 |
|
|
| Tsai 2003 |
1‐4 wk |
E: Hyalgan |
WOMAC pain (0‐100 mm VAS) |
100 |
45.73 |
23.21 |
‐3.31 (I) |
‐7.3% (I) |
| |
|
C: Saline |
|
98 |
45.09 |
25.88 |
|
|
| Tsai 2003 |
5‐13 wk |
E: Hyalgan |
WOMAC pain (0‐100 mm VAS) |
100 |
45.73 |
21.48 |
‐2.13 (I) |
‐4.7% (I) |
| |
|
C: Saline |
|
98 |
45.09 |
22.97 |
|
|
| Tsai 2003 |
14‐26 wk |
E: Hyalgan |
WOMAC pain (0‐100 mm VAS) |
100 |
45.73 |
16.48 |
‐6.30 (I) |
‐14.0% (I) |
| |
|
C: Saline |
|
98 |
45.09 |
22.14 |
|
|
| Tsai 2003 |
1‐4 wk |
E: Hyalgan |
WOMAC function (0‐100 mm VAS) |
100 |
46.54 |
26.91 |
‐2.83 (I) |
‐6.3% (I) |
| |
|
C: Saline |
|
98 |
45.01 |
28.21 |
|
|
| Tsai 2003 |
5‐13 wk |
E: Hyalgan |
WOMAC function (0‐100 mm VAS) |
100 |
46.54 |
24.25 |
‐2.59 (I) |
‐5.8% (I) |
| |
|
C: Saline |
|
98 |
45.01 |
25.31 |
|
|
| Tsai 2003 |
14‐26 wk |
E: Hyalgan |
WOMAC function (0‐100 mm VAS) |
100 |
46.54 |
20.85 |
‐5.58 (I) |
‐12.4% (I) |
| |
|
C: Saline |
|
98 |
45.01 |
24.90 |
|
|
| Carrabba 1995 |
1‐4 wk |
E: Hyalgan (5) |
Lequesne Index (0‐24) |
20 |
15.1 |
11.5 |
‐2.5 (I) |
‐17.2% (I) |
| |
|
C: Saline |
|
20 |
14.5 |
13.4 |
|
|
| Carrabba 1995a |
1‐4 wk |
E: Hyalgan (3) |
Lequesne Index (0‐24) |
20 |
14.9 |
11.6 |
‐2.2 (I) |
‐15.2% (I) |
| |
|
C: Saline |
|
20 |
14.5 |
13.4 |
|
|
| Carrabba 1995b |
1‐4 wk |
E: Hyalgan (5) |
Lequesne Index (0‐24) |
20 |
15.1 |
11.5 |
‐3.4 (I) |
‐23.8% (I) |
| |
|
C: Arthrocentesis |
|
20 |
14.3 |
14.1 |
|
|
| Carrabba 1995c |
1‐4 wk |
E: Hyalgan (3) |
Lequesne Index (0‐24) |
20 |
14.9 |
11.6 |
‐3.1 (I) |
‐21.7% (I) |
| |
|
C: Arthrocentesis |
|
20 |
14.3 |
14.1 |
|
|
| Dougados 1993 |
1‐4 wk |
E: Hyalectin |
Lequesne Index (0‐24) |
49 |
11.71 |
8.53 |
‐1.02 (I) |
‐9.32% (I) |
| |
|
C: Saline |
|
50 |
10.94 |
8.78 |
|
|
| Huskisson 1999 |
1‐4 wk |
E: Hyalgan |
Lequesne Index (0‐24) |
40 |
13.4 |
10.0 |
‐1.5 (I) |
‐10.7% (I) |
| |
|
C: Saline |
|
41 |
14.0 |
12.1 |
|
|
| Carrabba 1995 |
5‐13 wk |
E: Hyalgan (5) |
Lequesne Index (0‐24) |
20 |
15.1 |
11.6 |
‐2.9 (I) |
‐20% (I) |
| |
|
C: Saline |
|
20 |
14.5 |
13.9 |
|
|
| Carrabba 1995a |
5‐13 wk |
E: Hyalgan (3) |
Lequesne Index (0‐24) |
20 |
14.9 |
12.0 |
‐2.3 (I) |
‐15.9% (I) |
| |
|
C: Saline |
|
20 |
14.5 |
13.9 |
|
|
| Carrabba 1995b |
5‐13 wk |
E: Hyalgan (5) |
Lequesne Index (0‐24) |
20 |
15.1 |
11.6 |
‐3.6 (I) |
‐25.2% (I) |
| |
|
C: Arthrocentesis |
|
20 |
14.3 |
14.4 |
|
|
| Carrabba 1995c |
5‐13 wk |
E: Hyalgan (3) |
Lequesne Index (0‐24) |
20 |
14.9 |
12.0 |
‐3.0 (I) |
‐21% (I) |
| |
|
C: Arthrocentesis |
|
20 |
14.3 |
14.4 |
|
|
| Huskisson 1999 |
5‐13 wk |
E: Hyalgan |
Lequesne Index (0‐24) |
40 |
13.4 |
10.2 |
‐1.6 (I) |
‐11.4% (I) |
| |
|
C: Saline |
|
41 |
14.0 |
12.4 |
|
|
| Huskisson 1999 |
14‐26 wk |
E: Hyalgan |
Lequesne Index (0‐24) |
40 |
13.4 |
11.2 |
‐0.8 (I) |
‐5.7% (I) |
| |
|
C: Saline |
|
41 |
14.0 |
12.6 |
|
|
| Dougados 1993 |
45‐52 wk |
E: Hyalectin |
Lequesne Index (0‐24) |
47 |
11.71 |
7.06 |
‐1.88 (I) |
‐17.18% (I) |
| |
|
C: Saline |
|
47 |
10.94 |
8.17 |
|
|
